<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="/rss.css" type="text/css"?>
<rdf:RDF xmlns="http://purl.org/rss/1.0/"
    xmlns:cc="http://web.resource.org/cc/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:extra="http://www.w3.org/1999/xhtml"
    xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
    <channel rdf:about="http://www.cmjournal.org/feeds/latestarticles/journal?quantity=&amp;format=rss&amp;version=">
        <title>Chinese Medicine - Latest Articles</title>
        <link>http://www.cmjournal.org</link>
        <description>The latest research articles published by Chinese Medicine</description>
        <dc:date>2013-05-17T00:00:00Z</dc:date>
        <items>
            <rdf:Seq>
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/11" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/10" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/9" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/8" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/7" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/6" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/5" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/4" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/3" />
                                <rdf:li rdf:resource="http://www.cmjournal.org/content/8/1/2" />
                            </rdf:Seq>
        </items>
                 <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </channel>
        <item rdf:about="http://www.cmjournal.org/content/8/1/11">
        <title>Anti-hyperglycaemic activity of swietenia macrophylla king (meliaceae) seed extracts in normoglycaemic rats undergoing glucose tolerance tests</title>
        <description>Background:
Swietenia macrophylla King (Meliaceae) is used to treat diabetes mellitus in Malaysia. This study aims to evaluate the anti-hyperglycaemic potential of petroleum ether (PE), chloroform (CE) and methanol (ME) extracts of S. macrophylla seeds, in normoglycaemic and streptozotocin (STZ)-induced diabetic rats.
Methods:
Following treatment of normoglycaemic rats with S. macrophylla seed extracts, hypoglycaemia and intraperitoneal glucose tolerance tests (IPGTT) were performed, and blood glucose concentrations were measured. Similarly, glucose concentrations were measured after 1 and 14 days of extract treatment of STZ-induced diabetic rats. Glucose absorption by isolated everted intestine and glucose uptake by isolated abdominal muscle were tested after treatment with seed extracts. Gas chromatography mass spectrometry (GC-MS) analysis was performed on PE of S. macrophylla seeds to identify the compounds responsible for its activity.
Results:
None of the extracts had a significant effect on the blood glucose levels of 60 randomly selected normoglycaemic (normal) and diabetic rats undergoing hypoglycaemia tests. PE, however, significantly reduced blood glucose levels in 30 randomly selected normoglycaemic rats undergoing IPGTT tests 30--120 minutes after glucose administration. Repeated doses of 1000 mg/kg and 500 mg/kg PE to STZ-induced diabetic rats for 14 days did not reduce blood glucose levels significantly. PE did not reduce significantly reduce the intestinal absorption of glucose, but significantly increased glucose uptake by abdominal muscle in the absence or presence of insulin. GC-MS analysis indicated thatditerpenes, triterpenoids, fatty acid methyl esters, aldehydes and phytosterols may be responsible for the glucose lowering effects of PE.
Conclusion:
PE extracts of S. macrophylla seeds PE showed anti-hyperglycaemic activity on IPGTTs . GC-MS analysis on the PE revealed that several compounds, including fucosterol and beta-sitosterol, may be responsible for these anti-hyperglycaemic properties.</description>
        <link>http://www.cmjournal.org/content/8/1/11</link>
                <dc:creator>Mohd Hashim</dc:creator>
                <dc:creator>Mun Yam</dc:creator>
                <dc:creator>Sook Hor</dc:creator>
                <dc:creator>Chung Lim</dc:creator>
                <dc:creator>Mohd Asmawi</dc:creator>
                <dc:creator>Amirin Sadikun</dc:creator>
                <dc:source>Chinese Medicine 2013, null:11</dc:source>
        <dc:date>2013-05-17T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-11</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-11-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>11</prism:startingPage>
        <prism:publicationDate>2013-05-17T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>PDF</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/10">
        <title>Developing a diagnostic checklist of traditional Chinese medicine symptoms and signs for psoriasis: a Delphi study</title>
        <description>Background:
Psoriasis is a chronic inflammatory skin disease with a genetic basis. Its ill-defined causes make it difficult to diagnose. This study aims to develop a diagnostic checklist for psoriasis classification in the context of traditional Chinese medicine.
Methods:
A Delphi study was conducted with three rounds by a panel of 16 dermatology experts to develop a checklist for traditional Chinese medicine symptoms and signs of psoriasis. Dermatology experts in psoriasis research, nine in Yunnan and seven in Beijing, were selected as the expert panel. The initial list of symptoms and signs in psoriasis was developed by reviewing the literature retrieved from Chinese and English journals. Experts rated each item of the list on a 5-point Likert scale. The list was revised and re-evaluated in the same manner for a total of 3 rounds before it was finalized.
Results:
One hundred and thirty items were extracted from the literature review. After three rounds of expert ratings, 96 items were retained with eight domains: color, type and shape of skin lesion, physical expression, tongue and coating, pulse, associated factors, and living environment. Intraclass correlation coefficient and Kappa statistics indicated an inter-rater agreement in the final checklist.
Conclusion:
A checklist containing 96 items in 8 domains was developed for psoriasis diagnosis using traditional Chinese medicine symptoms and signs.</description>
        <link>http://www.cmjournal.org/content/8/1/10</link>
                <dc:creator>Xuesong Yang</dc:creator>
                <dc:creator>Virasakdi Chongsuvivatwong</dc:creator>
                <dc:creator>Edward McNeil</dc:creator>
                <dc:creator>Jianzhou Ye</dc:creator>
                <dc:creator>Xiaoyong Ouyang</dc:creator>
                <dc:creator>Enpin Yang</dc:creator>
                <dc:creator>Hutcha Sriplung</dc:creator>
                <dc:source>Chinese Medicine 2013, null:10</dc:source>
        <dc:date>2013-05-12T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-10</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-10-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>10</prism:startingPage>
        <prism:publicationDate>2013-05-12T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/9">
        <title>Time course changes of anti- and pro-apoptotic proteins in apigenin-induced genotoxicity</title>
        <description>Background:
Apigenin (4&#8242;,5,7-trihydroxyflavone, AP), an active component of many medicinal Chinese herbs, exhibits anticancer properties in vitro and in vivo. This study aims to investigate the genotoxic, cytostatic, and cytotoxic effects of AP and time course changes in the levels of anti- and pro-apoptotic proteins involved in the DNA damage response in HepG2 cells.
Methods:
The genotoxic potential of AP was determined by sister chromatid exchanges (SCEs) and chromosomal aberrations (CAs) analysis. The levels of cytostaticity and cytotoxicity were evaluated by the proliferation rate and mitotic indices, respectively. MTT was used to study cytotoxicity, while the induction of apoptosis and the expression of apoptosis-related proteins were determined by ELISA.
Results:
At concentrations greater than 10 &#956;M, AP decreased cell survival in a dose- (48 h: 10 vs. 20 &#956;&#924;, P&#8201;&lt;&#8201;0.001 and 20 vs. 50 &#956;&#924;, P&#8201;=&#8201;0.005; 72 h: 10 vs. 20 &#956;&#924;, P&#8201;&lt;&#8201;0.001 and 20 vs. 50 &#956;&#924;, P&#8201;=&#8201;0.001) and time-dependent manner (20 &#956;&#924;: 24 vs. 48 h, P&#8201;&lt;&#8201;0.001 and 48 vs. 72 h, P&#8201;=&#8201;0.003; 50 &#956;&#924;: 24 vs. 48 h, P&#8201;&lt;&#8201;0.001 and 48 vs. 72 h, P&#8201;&lt;&#8201;0.001; 100 &#956;&#924;: 24 vs. 48 h, P&#8201;&lt;&#8201;0.001 and 48 vs. 72 h, P&#8201;&lt;&#8201;0.001). SCEs rates, cell proliferation, and mitotic divisions were also affected in a dose-dependent manner (P&#8201;&lt;&#8201;0.001). There was no change in the frequency of aberrant cells (1 &#956;&#924; &#913;P: P&#8201;=&#8201;0.554; 10 &#956;M AP: P&#8201;=&#8201;0.337; 20 &#956;&#924; AP: P&#8201;=&#8201;0.239). Bcl-2 levels were reduced 3 h after AP administration (P&#8201;=&#8201;0.003) and remained reduced throughout the 48 h observation period (6 h, P&#8201;=&#8201;0.044; 12 h, P&#8201;=&#8201;0.001; 24 h, P&#8201;=&#8201;0.042; 48 h, P&#8201;=&#8201;0.012). Bax and soluble Fas exhibited a transient upregulation 24 h after AP treatment. The Bax/Bcl-2 ratio was also increased at 12 h and remained increased throughout the 48 h observation period.
Conclusion:
AP exhibited dose-dependent genotoxic potential in HepG2 cells. The protein levels of sFas, Bcl-2, and Bax were affected by AP to promote cell survival and cell death, respectively.</description>
        <link>http://www.cmjournal.org/content/8/1/9</link>
                <dc:creator>Fotini Papachristou</dc:creator>
                <dc:creator>Ekaterini Chatzaki</dc:creator>
                <dc:creator>Athanasios Petrou</dc:creator>
                <dc:creator>Ioanna Kougioumtzi</dc:creator>
                <dc:creator>Nikolaos Katsikogiannis</dc:creator>
                <dc:creator>Alexandros Papalambros</dc:creator>
                <dc:creator>Grigorios Tripsianis</dc:creator>
                <dc:creator>Constantinos Simopoulos</dc:creator>
                <dc:creator>Alexandra Tsaroucha</dc:creator>
                <dc:source>Chinese Medicine 2013, null:9</dc:source>
        <dc:date>2013-05-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-9</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-9-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>9</prism:startingPage>
        <prism:publicationDate>2013-05-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/8">
        <title>Referral to Chinese medicine practitioners in Australian primary care: a survey of New South Wales rural and regional general practitioners</title>
        <description>Background:
Chinese medicine practitioners (CMPs) play an important part in rural and regional Australian healthcare. A survey was conducted to investigate referral practices between Chinese medicine (CM) and conventional primary health care practitioners in this region.
Methods:
A 27-item questionnaire was sent to all 1486 general practitioners (GPs) currently practising in rural and regional Divisions of General Practice in New South Wales, Australia. This survey explored GP opinions, perceptions and practices in relation to complementary and alternative medicine or Chinese medicine specifically.
Results:
A total of 585 GPs completed the questionnaire. Forty-nine were returned as &#8216;no longer at this address&#8217;, resulting in an adjusted response rate of 40.7%. One in ten GPs (9.9%) had referred their patients to CMPs at least a few times over the past 12&#160;months, one in five GPs (17.4%) could not locate a CMP to refer to in their local area, and over one-third of GPs (37.7%) stated they would not refer to a CMP under any circumstances. GPs that had graduated from an Australian medical college (OR = 3.71; CI: 1.22, 11.23), GPs observing positive responses previously in patients using CM (OR = 2.53; 95% CI: 1.12, 8.58), GPs perceiving a lack of other options for patients (OR = 3.10; 95% CI: 1.12, 8.58), GPs reporting satisfactory or higher levels of CM knowledge (OR = 15.62; 95% CI: 5.47, 44.56), and GPs interested in increasing their complementary and alternative medicine knowledge (OR = 3.28; 95% CI: 1.17, 9.21) referred to CMPs more frequently than did other groups of GPs amongst the rural GPs included in this study.
Conclusion:
There has been little interaction between CMPs and Australian rural and regional GPs.</description>
        <link>http://www.cmjournal.org/content/8/1/8</link>
                <dc:creator>Jonathan Wardle</dc:creator>
                <dc:creator>David Sibbritt</dc:creator>
                <dc:creator>Jon Adams</dc:creator>
                <dc:source>Chinese Medicine 2013, null:8</dc:source>
        <dc:date>2013-04-08T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-8</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-8-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>8</prism:startingPage>
        <prism:publicationDate>2013-04-08T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/7">
        <title>Hepatoprotective effect of water extract from Chrysanthemum indicum L. flower</title>
        <description>Background:
Chrysanthemum indicum L. flower (CIF) has been widely used as tea in Korea. This study aims to investigate the hepatoprotective effect of the hot water extract of CIF (HCIF) in in vitro and in vivo systems.
Methods:
Hepatoprotective activities were evaluated at 250 to 1000&#160;&#956;g/mL concentrations by an in vitro assay using normal human hepatocytes (Chang cell) and hepatocellular carcinoma cells (HepG2) against CCl4-induced cytotoxicity. Cytochrome P450 2E1, which is a key indicator of hepatic injury, was detected by western blot analysis using rabbit polyclonal anti-human CYP2E1 antibody. An in vivo hepatoprotective activity assay was performed at 1000 to 4000&#160;&#956;g/mL concentrations on CCl4-induced acute toxicity in rats, and the serum levels of glutamic oxaloacetic transaminase (GOT), glutamic pyruvic transaminase (GPT), alkaline phosphatase (ALP) and lactate dehydrogenase (LDH) were determined by standard enzyme assays.
Results:
The hepatoprotective effects of HCIF significantly reduced the levels of GOT (60.1%, P&#8201;=&#8201;0.000) and GPT (64.5%, P&#8201;=&#8201;0.000) compared with the vehicle control group (CCl4 alone). The survival rates of HepG2 and Chang cells were significantly improved compared with the control group [82.1% (P&#8201;=&#8201;0.034) and 62.3% (P&#8201;=&#8201;0.002), respectively]. HCIF [50&#160;mg/kg body weight (BW)] treatment significantly reduced the serum levels of GOT (49.5%, P&#8201;=&#8201;0.00), GPT (55.5%, P&#8201;=&#8201;0.00), ALP (30.8%, P&#8201;=&#8201;0.000) and LDH (45.6%, P&#8201;=&#8201;0.000) compared with the control group in this in vivo study. The expression level of cytochrome P450 2E1 (CYP2E1) protein was also significantly decreased at the same concentration (50&#160;mg/kg BW; P&#8201;=&#8201;0.018).
Conclusion:
HCIF inhibited bioactivation of CCl4-induced hepatotoxicity and downregulates CYP2E1 expression in vitro and in vivo.</description>
        <link>http://www.cmjournal.org/content/8/1/7</link>
                <dc:creator>Sang Chul Jeong</dc:creator>
                <dc:creator>Sang Min Kim</dc:creator>
                <dc:creator>Yong Tae Jeong</dc:creator>
                <dc:creator>Chi Hyun Song</dc:creator>
                <dc:source>Chinese Medicine 2013, null:7</dc:source>
        <dc:date>2013-04-04T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-7</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-7-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>7</prism:startingPage>
        <prism:publicationDate>2013-04-04T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/6">
        <title>Annual acknowledgement of manuscript reviewers</title>
        <description>Contributing reviewersThe editors of Chinese Medicine would like to thank all our reviewers who have contributed to the journal in Volume 7 (2012).</description>
        <link>http://www.cmjournal.org/content/8/1/6</link>
                <dc:creator>Siu-wai Leung</dc:creator>
                <dc:source>Chinese Medicine 2013, null:6</dc:source>
        <dc:date>2013-03-20T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-6</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-6-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>6</prism:startingPage>
        <prism:publicationDate>2013-03-20T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/5">
        <title>Chemical fingerprinting and quantitative constituent analysis of Siwu decoction categorized formulae by UPLC-QTOF/MS/MS and HPLC-DAD</title>
        <description>Background:
Siwu decoction categorized formulae (SWDCF) are widely used for treating gynecological diseases. This study aims to elucidate the differences of bioactive constituents in SWDCF by ultra-high performance liquid chromatography coupled with time-of-flight mass spectrometry (UPLC - QTOF - MS /MS) and HPLC-DAD.
Methods:
An efficient method based on UPLC - QTOF - MS /MS was developed for identifying the chemical profiles of SWDCF. HPLC-DAD method was used for quantifying seven chemical markers in SWDCF.
Results:
Eighty four components were identified or characterized, including ten organic acids, thirty glycosides (monoterpene or iridoid or phenylpropanoids glycosides), fourteen lactones, eighteen flavonoids, and eleven alkaloids in the complex system. The datasets of tR-m/z pairs, ion intensities and sample codes were processed with supervised orthogonal partial least squared discriminant analysis to compare these decoction samples. After a clear classification was established, OPLS-DA was performed and 16 common components with relative quantity in SWDCF samples were determined. Gallic acid, protocatechuic acid, vanillic acid, caffeic acid, paeoniflorin, ferulic acid, and senkyunolide I were selected as the chemical markers to identify SWDCF by HPLC-DAD.
Conclusion:
The chemical profiles with 84 components in SWDCF, including monoterpene glycosides, acetophenones, galloyl glucoses, even some isomers in the complex system were characterized by UPLC&#8211;QTOF&#8211;MS/MS.</description>
        <link>http://www.cmjournal.org/content/8/1/5</link>
                <dc:creator>Shulan Su</dc:creator>
                <dc:creator>Wenxia Cui</dc:creator>
                <dc:creator>Wei Zhou</dc:creator>
                <dc:creator>Jin-ao Duan</dc:creator>
                <dc:creator>Erxin Shang</dc:creator>
                <dc:creator>Yuping Tang</dc:creator>
                <dc:source>Chinese Medicine 2013, null:5</dc:source>
        <dc:date>2013-03-01T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-5</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-5-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>5</prism:startingPage>
        <prism:publicationDate>2013-03-01T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/4">
        <title>Effects of Panax ginseng-containing herbal plasters on compressed intervertebral discs in an in vivo rat tail model</title>
        <description>Background:
Tienchi (Panax notoginseng) has been used in conservative treatments for back pain as a major ingredient of many herbal medicines. This study aims to investigate the effects of a herbal medicine containing tienchi on compressed intervertebral discs in rats.
Methods:
Using an in vivo rat tail model, intervertebral disc compression was simulated in the caudal 8&#8211;9 discs of 25 rats by continuous static compression (11 N) for 2 weeks. An herbal medicine plaster (in which the major ingredient was tienchi) was externally applied to the compressed disc (n=9) for three weeks, and held in place by an adhesive bandage, in animals in the Chinese Medicine (CM) group. The effect of the bandage was evaluated in a separate placebo group (n=9), while no intervention with unrestricted motion was provided to rats in an additional control group (n=7). Disc structural properties were quantified by in vivo disc height measurement and in vitro morphological analysis.
Results:
Disc height decreased after the application of compression (P &lt; 0.001). The disc height decreased continuously in the control (P = 0.006) and placebo (P = 0.003) groups, but was maintained in the CM group (P = 0.494). No obvious differences in disc morphology were observed among the three groups (P = 0.896).
Conclusion:
The tienchi-containing herbal plaster had no significant effect on the morphology of compressed discs, but maintained disc height in rats.</description>
        <link>http://www.cmjournal.org/content/8/1/4</link>
                <dc:creator>Daniel H Chow</dc:creator>
                <dc:creator>Alon Lai</dc:creator>
                <dc:creator>Fuk-Hay Tang</dc:creator>
                <dc:creator>Mason C Leung</dc:creator>
                <dc:source>Chinese Medicine 2013, null:4</dc:source>
        <dc:date>2013-02-18T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-4</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-4-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>4</prism:startingPage>
        <prism:publicationDate>2013-02-18T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/3">
        <title>Key considerations for conducting Chinese medicine clinical trials in hospitals</title>
        <description>Conducting clinical trials of Chinese medicines (CM) in hospitals presents challenges for researchers. The success of hospital-based CM clinical trials may be influenced by the protocol design, including the maintenance of CM theory in compliance with scientific rigour and hospital guidelines and justified treatment approaches with results that can translate into clinical practice. Other influences include personnel and resources such as a dedicated team open to CM with an established research culture and the ability to maximise participant recruitment. This article identifies the key challenges and limitations of conducting CM clinical trials in Australian hospitals.</description>
        <link>http://www.cmjournal.org/content/8/1/3</link>
                <dc:creator>Johannah Shergis</dc:creator>
                <dc:creator>Shefton Parker</dc:creator>
                <dc:creator>Meaghan Coyle</dc:creator>
                <dc:creator>Anthony Zhang</dc:creator>
                <dc:creator>Charlie Xue</dc:creator>
                <dc:source>Chinese Medicine 2013, null:3</dc:source>
        <dc:date>2013-02-16T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-3</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-3-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>3</prism:startingPage>
        <prism:publicationDate>2013-02-16T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <item rdf:about="http://www.cmjournal.org/content/8/1/2">
        <title>Changes in the contents of four active diterpenoids at different growth stages in Andrographis paniculata (Burm.f.) Nees (Chuanxinlian)</title>
        <description>Background:
The therapeutic activities of Andrographis paniculata are attributed to four major active diterpenoids: andrographolide (AP1), 14-deoxy-11,12-didehydroandrographolide (AP3), neoandrographolide (AP4), and 14-deoxyandrographolide (AP6). This study aims to quantify the four active diterpenoids in various plant organs of A. paniculata at different growth stages in greenhouse and field experiments, with a developed HPLC-diode array detector (HPLC-DAD) method for simultaneous determination of these diterpenoids.
Methods:
Plants were grown in greenhouse and in field conditions, harvested at different growth stages, and separated into different organs for determination of the four active diterpenoids by an HPLC-DAD method.
Results:
The most abundant diterpenoid was AP6 between seedling and vegetative stages in the greenhouse experiment (13.38 to 23.71 mg/g in 2006 and 10.67 to 24.54 mg/g in 2007). High levels of AP6 were also detected in leaves at the transfer stage in the greenhouse experiment (36.05&#8201;&#177;&#8201;0.69 mg/g) and field experiment (30.59&#8201;&#177;&#8201;1.39 mg/g). The levels of AP6 then decreased as plants matured. The highest content of AP4 was in cotyledons (16.65&#8201;&#177;&#8201;4.48 mg/g) at the transfer stage. The highest contents of AP1 were detected in leaves at seed-forming stage in greenhouse experiment (24.72&#8201;&#177;&#8201;1.89 mg/g) and vegetative stage in field experiment (43.16&#8201;&#177;&#8201;0.92 mg/g). Flowers of A. paniculata contained high levels of AP1 (21.42&#8201;&#177;&#8201;3.74 mg/g). AP3 and AP4 were at low levels in leaves at all growth stages.
Conclusion:
In A. paniculata, AP6 was at the highest level in leaves at transfer stage in both greenhouse and field experiments. AP1 was at the highest level in leaves at vegetative stage and seed-forming stage in field and greenhouse experiments, respectively. The contents of AP3 and AP4 in leaves were low at all growth stages.</description>
        <link>http://www.cmjournal.org/content/8/1/2</link>
                <dc:creator>Nanthanit Pholphana</dc:creator>
                <dc:creator>Nuchanart Rangkadilok</dc:creator>
                <dc:creator>Jittra Saehun</dc:creator>
                <dc:creator>Supachai Ritruechai</dc:creator>
                <dc:creator>Jutamaad Satayavivad</dc:creator>
                <dc:source>Chinese Medicine 2013, null:2</dc:source>
        <dc:date>2013-01-15T00:00:00Z</dc:date>
        <dc:identifier>doi:10.1186/1749-8546-8-2</dc:identifier>
                                <prism:require>/content/figures/1749-8546-8-2-toc.gif</prism:require>
                <prism:publicationName>Chinese Medicine</prism:publicationName>
        <prism:issn>1749-8546</prism:issn>
        <prism:volume>${item.volume}</prism:volume>
        <prism:startingPage>2</prism:startingPage>
        <prism:publicationDate>2013-01-15T00:00:00Z</prism:publicationDate>
                <prism:versionidentifier>XML</prism:versionidentifier>
                <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/" />
    </item>
        <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
        <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution" />
        <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks" />
    </cc:License>
</rdf:RDF>
